Windlas Biotech received a regulatory show cause from Uttarakhand FDA, leading to a temporary halt in codeine-based cough syrup production. Revenue impact noted for the line is ₹55.21 crore as of Feb 9, 2026, with other products unaffected.
AI Assistant
Windlas Biotech Ltd
2026
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.